Page 159 - Drug Class Review
P. 159
Drug Effectiveness Review Project
galantamine 24 mg/d placebo galantamine 32 mg/d 78.9% 92.4% 92.0% 13.1% 43.6% 37.3% 7.5% 25.6% 20.8% 11.3% 18.5% 13.7% 9.9% 19.4% 12.3% 5.6% 20.4% 13.7% 4.7% 10.9% 12.3% 4.2% 10.9% 6.6% ation exclusions: NR Overall loss to follow-up: 31.1% Yes Loss to follow-up differential high: placebo galantamine 32 mg/d galantamine 24 mg/d 19.2% 42.2% 32.1% 7.5% 31.8% 23.1% Page 110 of 205
NR ITT: Yes Post randomiz Yes Yes Yes Fair
rse events:
Final Report Update 1 Authors: Raskind et al. Year: 2000 ADVERSE EVENTS: Overall adverse effects reported: Nausea • Vomiting • Dizziness • Diarrhea • Anorexia • Weight loss • Abdominal pain • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adve QUALITY RATING: *primary outcome measures Alzheimer's Drugs
